These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 27737744)

  • 41. Atherosclerosis: perspectives of anti-inflammatory therapy.
    Nasonov EL; Popkova TV
    Ter Arkh; 2018 May; 90(5):4-12. PubMed ID: 30701884
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.
    De Benedetti F; Gattorno M; Anton J; Ben-Chetrit E; Frenkel J; Hoffman HM; Koné-Paut I; Lachmann HJ; Ozen S; Simon A; Zeft A; Calvo Penades I; Moutschen M; Quartier P; Kasapcopur O; Shcherbina A; Hofer M; Hashkes PJ; Van der Hilst J; Hara R; Bujan-Rivas S; Constantin T; Gul A; Livneh A; Brogan P; Cattalini M; Obici L; Lheritier K; Speziale A; Junge G
    N Engl J Med; 2018 May; 378(20):1908-1919. PubMed ID: 29768139
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study.
    Zinman B; Harris SB; Neuman J; Gerstein HC; Retnakaran RR; Raboud J; Qi Y; Hanley AJ
    Lancet; 2010 Jul; 376(9735):103-11. PubMed ID: 20605202
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High plasma levels of macrophage migration inhibitory factor are associated with adverse long-term outcome in patients with stable coronary artery disease and impaired glucose tolerance or type 2 diabetes mellitus.
    Makino A; Nakamura T; Hirano M; Kitta Y; Sano K; Kobayashi T; Fujioka D; Saito Y; Watanabe K; Watanabe Y; Kawabata K; Obata JE; Kugiyama K
    Atherosclerosis; 2010 Dec; 213(2):573-8. PubMed ID: 20934703
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Resveratrol Ameliorates Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Patients With Type 2 Diabetes Mellitus.
    Imamura H; Yamaguchi T; Nagayama D; Saiki A; Shirai K; Tatsuno I
    Int Heart J; 2017 Aug; 58(4):577-583. PubMed ID: 28701674
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance.
    Hanefeld M; Chiasson JL; Koehler C; Henkel E; Schaper F; Temelkova-Kurktschiev T
    Stroke; 2004 May; 35(5):1073-8. PubMed ID: 15073402
    [TBL] [Abstract][Full Text] [Related]  

  • 47. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.
    ; Bosch J; Gerstein HC; Dagenais GR; Díaz R; Dyal L; Jung H; Maggiono AP; Probstfield J; Ramachandran A; Riddle MC; Rydén LE; Yusuf S
    N Engl J Med; 2012 Jul; 367(4):309-18. PubMed ID: 22686415
    [TBL] [Abstract][Full Text] [Related]  

  • 48. One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1β.
    Blech M; Peter D; Fischer P; Bauer MM; Hafner M; Zeeb M; Nar H
    J Mol Biol; 2013 Jan; 425(1):94-111. PubMed ID: 23041424
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Arterial stiffness increases with deteriorating glucose tolerance status: the Hoorn Study.
    Henry RM; Kostense PJ; Spijkerman AM; Dekker JM; Nijpels G; Heine RJ; Kamp O; Westerhof N; Bouter LM; Stehouwer CD;
    Circulation; 2003 Apr; 107(16):2089-95. PubMed ID: 12695300
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Glucose intolerance is associated with C-reactive protein and intima-media anatomy of the common carotid artery in patients with coronary heart disease.
    Henareh L; Jogestrand T; Agewall S
    Diabet Med; 2005 Sep; 22(9):1212-7. PubMed ID: 16108851
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Examining the Role of and Treatment Directed at IL-1β in Atherosclerosis.
    Khan R; Rheaume E; Tardif JC
    Curr Atheroscler Rep; 2018 Sep; 20(11):53. PubMed ID: 30219977
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Elevated 1-h post-load plasma glucose levels in subjects with normal glucose tolerance are associated with a pro-atherogenic lipid profile.
    Andreozzi F; Mannino GC; Perticone M; Perticone F; Sesti G
    Atherosclerosis; 2017 Jan; 256():15-20. PubMed ID: 27940375
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
    Nicholls SJ; Puri R; Anderson T; Ballantyne CM; Cho L; Kastelein JJ; Koenig W; Somaratne R; Kassahun H; Yang J; Wasserman SM; Scott R; Ungi I; Podolec J; Ophuis AO; Cornel JH; Borgman M; Brennan DM; Nissen SE
    JAMA; 2016 Dec; 316(22):2373-2384. PubMed ID: 27846344
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The use of Canakinumab, a novel IL-1β long-acting inhibitor, in refractory adult-onset Still's disease.
    Kontzias A; Efthimiou P
    Semin Arthritis Rheum; 2012 Oct; 42(2):201-5. PubMed ID: 22512815
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sex differences in lipid profiles in relation to the progression of glucose abnormalities.
    Carnevale Schianca GP; Fra GP; Colli E; Bigliocca M; Mella R; Scaglia E; Bartoli E
    J Diabetes; 2012 Mar; 4(1):95-101. PubMed ID: 21951548
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impaired glucose tolerance is not associated with lipid intolerance.
    Henkel E; Temelkova-Kurktschiev T; Koehler C; Pietzsch J; Leonhardt W; Hanefeld M
    Diabetes Nutr Metab; 2002 Apr; 15(2):84-90. PubMed ID: 12059096
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of a long-term oral l-arginine supplementation on glucose metabolism: a randomized, double-blind, placebo-controlled trial.
    Monti LD; Setola E; Lucotti PC; Marrocco-Trischitta MM; Comola M; Galluccio E; Poggi A; Mammì S; Catapano AL; Comi G; Chiesa R; Bosi E; Piatti PM
    Diabetes Obes Metab; 2012 Oct; 14(10):893-900. PubMed ID: 22553931
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of acarbose treatment on markers of insulin sensitivity and systemic inflammation.
    Rudovich NN; Weickert MO; Pivovarova O; Bernigau W; Pfeiffer AF
    Diabetes Technol Ther; 2011 Jun; 13(6):615-23. PubMed ID: 21488802
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study.
    So A; De Meulemeester M; Pikhlak A; Yücel AE; Richard D; Murphy V; Arulmani U; Sallstig P; Schlesinger N
    Arthritis Rheum; 2010 Oct; 62(10):3064-76. PubMed ID: 20533546
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome.
    Torene R; Nirmala N; Obici L; Cattalini M; Tormey V; Caorsi R; Starck-Schwertz S; Letzkus M; Hartmann N; Abrams K; Lachmann H; Gattorno M
    Ann Rheum Dis; 2017 Jan; 76(1):303-309. PubMed ID: 27474763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.